

New Venturetec

NET ASSET VALUE - January 31, 2019

Shares issued private	4,500,000	Price: USD 23.83	USD 107'250'000
Shares issued IPO	500,000	Price: CHF 33.00 (ex.rate 1.47)	USD 11'250'000
	5,000,000		USD 118'500'000

Total paid in capital	USD	118,500,000.00
------------------------------	------------	-----------------------

Realized gain* (since inception to date)	USD	75,269,925.93
Realized loss* (since inception to date)	USD	109,585,211.82

*inclusive reinvestments

Investment appreciation of current portfolio companies

Unrealized gain	USD	36,660,690.80
Unrealized loss	USD	-184,400.71
Total appreciation	USD	36,476,290.09

NAV

Cost of investments	USD	28,475,733.64
Appreciation of investments	USD	36,476,290.09
Estimated value of investments	USD	64,952,023.73
Convertible Notes	USD	-13,277,710.66
Loan	USD	-7,696,927.11
Bank Loan	USD	0.00
Accrued expenses	USD	0.00
Accounts receivables	USD	0.00
Cash at bank	USD	83,186.31
Estimated value	USD	44,060,572.27
NAV per share USD		8.81
NAV per share CHF		8.75

Exchange rate USD/CHF	0.9933
Closing Market Price January 31, 2019	CHF 6.15

New Venturetec
NAV - January 31, 2019

INDUSTRY/ COMPANY	AMOUNT USD	% CAPITAL	SECURITIES	PRICE COST	PRICE REPORTED	UNREALIZED GAIN (LOSS)	TOTAL EST. VALUE	% NAV
1. Osiris Therapeutics, Inc.	23,780,932.93	83.5	4,103,301 Common Shares	5.80	14.73	36,660,690.80	60,441,623.73	93.0
2. Myriad Genetics	4,694,800.71	16.5	160,000 Shares	29.34	28.19	-184,400.71	4,510,400.00	6.9
TOTAL	28,475,733.64	100.0				36,476,290.09	64,952,023.73	99.9